Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Jun 6.
Published in final edited form as: Tetrahedron Lett. 2023 May 5;122:154521. doi: 10.1016/j.tetlet.2023.154521

Stereoselective synthesis of photoactivatable Man(β1,4)GlcNAc-based bioorthogonal probes

Abdullah A Hassan 1, Mia L Huang 1,2,*
PMCID: PMC10237449  NIHMSID: NIHMS1903183  PMID: 37274137

Abstract

We report an operationally facile protocol to prepare photoactivatable probes of the bioactive mammalian disaccharide, Man(β1,4)GlcNAc. Using conformationally restricted mannosyl hemi-acetal donors in a one-pot chlorination, iodination and glycosylation sequence, β-mannosides were generated in excellent diastereoselectivities and yields. Upon accessing the disaccharide, we generated the corresponding photoactivatable probes by appending a diazirine-alkyne equipped linker via a condensation reaction between a diazirine-containing linker and C-1 and C-2 derivatized mannosylamines to furnish the desired C-1 and C-2 modified Man(β1,4)GlcNAc-based probes. This new synthetic protocol greatly simplifies the preparation of this important bioactive disaccharide to enable future work to identify its protein binding partners in cells.

Keywords: Carbohydrate chemistry; stereoselective glycosylation; β-mannosylation; Man(β1,4)GlcNAc photoactivatable probes

Graphical Abstract

graphic file with name nihms-1903183-f0001.jpg

Introduction

Free oligosaccharides (fOs) are a class of structurally diverse, unconjugated (not bound to proteins or lipids) glycans that display a plethora of important biological functions. These activities range from antimicrobial and anti-inflammatory properties, to mediating signaling events and modulating the immune system.13 Despite the growing awareness of the role fOs play in human health and disease, the molecular mechanisms underlying many of these observed biological functions are not well understood. The inherent transient nature of fO-protein binding events coupled with the low binding affinity characteristic of most glycan-protein interactions, limits the use of conventional characterization tools,47 and requires the use of non-intrusive endogenous-like approaches to decipher such binding events in live cells.8, 9 10

The mammalian disaccharide, Man(β1,4)GlcNAc, is one such example of a bioactive mammalian autogenous fO with unknown binding interactions and important immune activating properties.11 As a result of aberrant hydrolysis of N-linked glycans by the oligosaccharyltransferase complex (OST), excess accumulation of Man(β1,4)GlcNAc occurs. The enhanced presence of Man(β1,4)GlcNAc in cells erroneously activates the innate immune system, manifesting phenotypes mimicking those found in autoimmunity. Man(β1,4)GlcNAc stimulates intracellular signaling pathways in a manner specific to both the glycosidic linkage (β) and the monosaccharide constituents.11, 12 Although the biogenesis and bioactivities of Man(β1,4)GlcNAc are known, its protein binding partners, and hence, its mechanism of action, remain elusive.11, 13, 14 As the aberrant hydrolysis step takes place in the cytosol, unambiguously identifying the postulated counter receptor residing in the cytosol remains a nontrivial endeavor.

The integration of photoaffinity labeling methods with mass spectrometry-based proteomic analysis provides an avenue to capture, enrich and identify the intracellular interactions between Man(β1,4)GlcNAc and its protein-based binding partners in live cells.1517 Recently, we reported the use of photoactivatable human milk oligosaccharide (HMO) probes appended with bifunctional linkers composed of a photoactivatable diazirine moiety for covalent entrapment of engaged proteins, and an alkyne reporter group to facilitate the analysis of HMO binding proteins via gel-based assays, various imaging techniques and mass spectrometry-based methods.18 This platform overcomes the inherent low affinity binding associated with glycan-protein interactions, and provides detailed examination of the proteome-wide binding events in situ.

Here, we describe an alternate and stereoselective synthesis of Man(β1,4)GlcNAc (1) and its corresponding C-1 and C-2 functionalized photoactivatable probes as tools to map its proteome-wide interactors and receptors. Previous synthetic protocols used to access Man(β1,4)GlcNAc suffered from poor stereoselectivity (<1:1 β:α) and low yields (< 43%).11, 1922 Stereoselective synthesis of 1,2-cis-β-linkages in mannosides can be challenging due to various stereoelectronic factors, such as the anomeric effect and neighboring group participation, favoring the antithetical α anomer.23, 24 Established strategies to access β-mannosides include the use of 4,6-benzylidene acetals to confer conformational control,25 employment of directing groups via intramolecular aglycone delivery,26, 27 direct anomeric O-glycosylation,28 and recently a one-pot chlorination-iodination-glycosylation sequence, which was developed by McGarrigle and co-workers (Fig 1).2931 We hypothesized that employing this SN2-type β-mannosylation strategy using conformationally constricted mannosyl hemi-acetals could improve the yield for glucosamine acceptors – a subtle limitation in this method.

Figure 1:

Figure 1:

(A) Key intermediates typically leveraged to induce β-selectivity in glycosylation reactions. (B) Synergistic use of conformationally restricted mannosyl donors with a SN2-type reaction to enhance β-selectivity.

Towards this end, we envisioned gaining access to β-linked photoaffinity probes by applying the elegant β-mannosylation protocol described by McGarrigle and co-workers to convert hemiacetal precursors in situ into reactive mannosyl iodide donors to facilitate a one-pot SN2-like glycosylation reaction with the corresponding GlcNAc acceptor.29 (Scheme 1) A brief retrosynthetic analysis of our targets provided a convergent approach to stereoselectively furnish the orthogonally protected disaccharide A from its mannosyl donor B and glucosaminyl acceptor C. Subsequent divergent orthogonal deprotection steps and functionalization sequences would give rise to our desired C-1 and C-2 modified photoactivatable probes.

Scheme 1:

Scheme 1:

Retrosynthetic analysis depicting the modular synthesis of Man(β1,4)GlcNAc and its corresponding C-1 and −2 diazirine-alkyne modified photoactivatable probes.

Results and Discussion

The preparation of the glucosylamine acceptor 7 commenced with the conversion of the amino functionality of readily available D-glucosamine to a phthalimido motif using phthalic anhydride and triethylamine. Temporary masking of all four hydroxy motifs as acetyl ester groups, followed by BF3.Et2O mediated conversion of the anomeric acetyl group into its corresponding benzyl glycoside, provided 4 in 73% over two steps (Scheme 2). Sequential synthetic steps comprising global removal of the acetyl protecting groups using catalytic quantities of NaOMe in anhydrous methanol accompanied by regioselective masking of the C-4 and C-6 hydroxy motifs as benzylidene acetals, and benzylation of the remaining C-3 hydroxy group afforded the fully protected glucosaminyl derivative 6 in 65% yield over 3 steps. Subsequent regioselective cleavage of the benzylidene ring using Et3SiH and triflic acid in anhydrous CH2Cl2 furnished the desired 4-OH glucosaminyl acceptor 7 in 87% yield. With 7 in hand, we turned our efforts toward the preparation of the corresponding mannosyl donors.

Scheme 2:

Scheme 2:

Synthesis of C4-OH glucosaminyl acceptor.

Guided by the knowledge that 4,6-benzylidene acetalic motifs are known to enhance beta selectivity and provide conformational rigidity for the ensuing glycosylation reaction,32, 33 peracetylated mannoside 9 was converted into its corresponding mannosyl thioglycoside 10 in 71% yield via treatment with thiophenol and BF·3Et2O in anhydrous CH2Cl2 (Scheme 3). Removal of the temporary acetyl protecting groups via Na2CO3 catalyzed methanolysis, followed by regioselective masking of the C-4 and C-6 hydroxy moieties afforded the benzylidene acetal protected intermediate 12 in a quantitative yield. Using milder benzylating conditions,34 12 was converted into its corresponding mono-benzylated derivative 13 by treatment with benzyl bromide, barium oxide and barium hydroxide in anhydrous DMF. To further explore and optimize the scope of the beta mannosylation method reported by Pongener et al,29 we opted to derivatize the C-2 and C-3 positions with benzyl and silyl ether groups. Accordingly, conversion of compound 13 into its di-benzylated derivative 14 was achieved by treatment with sodium hydride, tertbutyl ammonium bromide and benzyl bromide at elevated temperatures (140 °C).35 In the same vein, alcohol 13 was derivatized into tertbutyldimethyl silyl ether 15 and tertbutyldiphenyl silyl ether 16 in 73% and 61% yield, respectively.

Scheme 3:

Scheme 3:

Derivatization of mannosyl thioglycosides

We hypothesized that these ‘pseudo-armed’ benzyl substituents would compensate for the deactivating effect imposed by torsional strain caused by the 4,6-benzylidene ring.36, 37 Bulky silyl protecting groups are also known to confer ‘super-armed’ to their respective glycosyl donors.38, 39 Facile removal of the silyl ether protecting at C-2 to facilitate future oligosaccharide elongation was another key impetus for silyl ether functionalization at this position. Mannosyl thioglycoside donors 14–15 were converted into their corresponding hemi-acetal analogues in yields ranging from 42% to 80% (Scheme 4).

Scheme 4:

Scheme 4:

Hydrolysis of thiophenyl glycosides

With the glucosaminyl acceptor (7) and mannosyl (17–19) donors in hand, we began exploring the feasibility of applying the elegant β-mannosylation developed by McGarrigle and co-workers using silyl ether protected 18 as our initial donor (Table 1). Conversion of 18 into its corresponding mannosyl chloride using (COCl)2, Ph3PO and subsequent halide methathesis by addition of LiI, diisopropylethylamine (DIPEA) and acceptor 7 at room temperature resulted in low yield and no stereoselectivity (entry 1). Elevation of reaction temperature (45 °C) coupled with increased times (24 h to 48 h) resulted in furnishing 21β in 69% with high beta stereoselectivity (15:1, β:α) (entry 3). Formation of compound 21β and subsequent was confirmed by high resolution mass spectrometry, and the anomeric configuration was verified by the presence of 1H NMR diagnostic anomeric singlet at 5.50 ppm, as well as the 1J1CH = 155.1 Hz coupling between the anomeric proton and its adjacent carbon.40, 41 Efforts to substitute LiI to other iodination sources, such as tertbutylammonium iodide (TBAI), resulted in the loss of stereoselectivity for the desired anomer (entry 4). It should be noted at scale above 500 mg, cleavage of silyl ether protecting group occurs resulting complex mixture of products. Similarly, minor cleavage of the benzylidene acetal was observed at reaction temperature exceeding 45 °C. With the knowledge that elevated temperature and reaction duration greatly increased our desired outcome for hemiacetal 18, we employed the optimized reaction conditions for the di-benzylated and silyl ether derivatives 17 and 19. As hypothesized previously, complete β-stereoselectivity and an excellent yield was obtained with the di-benzylated derivative 17 (entry 5). Similarly, excellent stereoselectivity and yield was obtained for the ‘super-armed’ silyl ether containing compound 22β.

Table 1:

Optimization of β-mannosylation reaction

graphic file with name nihms-1903183-t0002.jpg
Entry Hemiacetal Promoter Solvent Temp Time β/α ratioa Product Yield
1 18 Ph3PO, (COCl)2, LiI CHCl3 rt 12 h 1:1 38% (21)
2 18 Ph3PO, (COCl)2, LiI CHCl3 45 °C 24 h 2.5:1 61% (21)
3 18 Ph3PO, (COCl)2, LiI CHCl3 45 °C 48 h 15:1 69%b (21β)
4 18 Ph3PO, (COCl)2, TBAI CHCl3: CH3CN 45 °C 48 h 1:2 53% (21)
5 17 Ph3PO, (COCl)2, LiI CHCl3 45 °C 48 h β only 75b (20β)
6 19 Ph3PO, (COCl)2, LiI CHCl3 45 °C 48 h 9:1 89%b (22β)
a

Determined by 1H NMR analysis of the crude reaction mixture.

b

Isolated yield of β-anomer.

With our desired β-configured disaccharides in hand, we began our efforts toward installing the photoactivatable diazirine tag at C-1 and C-2 position of glucosamine (Scheme 5). To this end, silyl ether cleavage and hydrogenolysis of compounds 20, 21 and 22 with Pd/C and H2 produced the key deprotected intermediate 23 required for divergent access to the desired C-1 and C-2 probes. Thus, hemiacetal 23 was converted into its corresponding amine analogue via treatment with ammonium carbonate in anhydrous DMSO under microwave irradiation conditions.18, 42 Subsequent condensation with diazirine-alkyne-acid linker by conventional amide bond coupling protocol produced the desired C-1 probe, which was used in the subsequent steps without further purification. Upon removal of the N-phthalimido moiety, sequential acetylation and deacetylation sequences furnished the C-1 probe (1) in 31% yield over 4 steps. Similarly, N-phathalimido cleavage by exposure of 23 to hydrazine, followed by EDC and HOBT mediated condensation between 25 and a diazirine-alkyne-acid linker generated the corresponding C-2 diazirine-equipped Man(β1,4)GlcNAc (2) in 55% from intermediate 23.

Scheme 5:

Scheme 5:

Orthogonal deprotection of divergently functionalized disaccharides (2022), and subsequent EDC and HOBT mediated amide bond formation to generate the C-1 and C-2 diazirine equipped probes.

Conclusion

In summary, we describe an operationally facile protocol for the stereoselective synthesis of Man(β1,4)GlcNAc and its corresponding C-1 and C-2-diazirine-alkyne equipped analogues. A key defining feature in our synthesis relies on the use of a previously disclosed β-mannosylation protocol coupled with the use of conformationally restricted glycosyl donors to facilitate the requisite stereoselective SN2-type reaction. In addition to the immune activating properties displayed by Man(β1,4)GlcNAc, it is also a conserved core motif found within N-linked glycoproteins. Thus, facile access to relatively high yielding, stereoselective protocols to furnish this disaccharide is desirable. We anticipate these probes can be deployed as bioorthogonal tools to survey their respective protein binders in live cells, cell lysates, or purified recombinant proteins.

Supplementary Material

1

Acknowledgments

A.A.H. and M.L.H. are supported by the NIGMS (R35GM142462). The acquisition of 600 MHz nuclear magnetic resonance spectra was supported by the NIH (S10OD021550).

Declaration of interests

Mia L. Huang reports financial support was provided by The Scripps Research Institute.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Molina A, O’Neill MA, Darvill AG, Etzler ME, Mohnen D, Hahn MG and Esko JD, in Essentials of Glycobiology, eds. th, Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, Mohnen D, Kinoshita T, Packer NH, Prestegard JH, Schnaar RL and Seeberger PH, Cold Spring Harbor; (NY: ), 2022, DOI: 10.1101/glycobiology.4e.40, pp. 539–548. [DOI] [Google Scholar]
  • 2.Bode L, Early Hum Dev, 2015, 91, 619–622. [DOI] [PubMed] [Google Scholar]
  • 3.Foata F, Sprenger N, Rochat F and Damak S, Scientific Reports, 2020, 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hirabayashi J, Yamada M, Kuno A and Tateno H, Chemical Society Reviews, 2013, 42, 4443. [DOI] [PubMed] [Google Scholar]
  • 5.Oyelaran O and Gildersleeve JC, Current Opinion in Chemical Biology, 2009, 13, 406–413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Haseley SR, Talaga P, Kamerling JP and Vliegenthart JFG, Analytical Biochemistry, 1999, 274, 203–210. [DOI] [PubMed] [Google Scholar]
  • 7.Valverde P, Quintana JI, Santos JI, Ardá A and Jiménez-Barbero J, ACS Omega, 2019, 4, 13618–13630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Joffrin AM and Hsieh-Wilson LC, J Am Chem Soc, 2020, 142, 13672–13676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Vilen Z, Reeves AE and Huang ML, Israel Journal of Chemistry, 2023, DOI: 10.1002/ijch.202200097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Wibowo A, Peters EC and Hsieh-Wilson LC, Journal of the American Chemical Society, 2014, 136, 9528–9531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fermaintt CS, Sano K, Liu Z, Ishii N, Seino J, Dobbs N, Suzuki T, Fu YX, Lehrman MA, Matsuo I and Yan N, Nat Commun, 2019, 10, 2377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, Jiang S, Li QZ, Atkinson JP, Morse HC 3rd, Lehrman MA and Yan N, Immunity, 2015, 43, 463–474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yan N, Journal of Interferon & Cytokine Research, 2017, 37, 198–206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sakai T, Miyazaki T, Shin D-M, Kim Y-S, Qi C-F, Fariss R, Munasinghe J, Wang H, Kovalchuk AL, Kothari PH, Fermaintt CS, Atkinson JP, Perrino FW, Yan N and Morse HC, Journal of Autoimmunity, 2017, 81, 13–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Murale DP, Hong SC, Haque MM and Lee J-S, Proteome Science, 2016, 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wu H and Kohler J, Curr Opin Chem Biol, 2019, 53, 173–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Conway LP, Li W and Parker CG, Cell Chem Biol, 2021, 28, 371–393. [DOI] [PubMed] [Google Scholar]
  • 18.Hassan AA, Wozniak JM, Vilen Z, Li W, Jadhav A, Parker CG and Huang ML, RSC Chemical Biology, 2022, 3, 1369–1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Shaban MA and Jeanloz RW, Carbohydr Res, 1976, 52, 115–127. [DOI] [PubMed] [Google Scholar]
  • 20.Paulsen H and Lebuhn R, Liebigs Annalen der Chemie, 1983, 1983, 1047–1072. [Google Scholar]
  • 21.Li B, Zeng Y, Hauser S, Song H and Wang L-X, Journal of the American Chemical Society, 2005, 127, 9692–9693. [DOI] [PubMed] [Google Scholar]
  • 22.Yang W, Ramadan S, Orwenyo J, Kakeshpour T, Diaz T, Eken Y, Sanda M, Jackson JE, Wilson AK and Huang X, Chemical Science, 2018, 9, 8194–8206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gridley JJ and Osborn HMI, Journal of the Chemical Society, Perkin Transactions 1, 2000, DOI: 10.1039/a909165c, 1471–1491. [DOI] [Google Scholar]
  • 24.Wiberg KB, Bailey WF, Lambert KM and Stempel ZD, The Journal of Organic Chemistry, 2018, 83, 5242–5255. [DOI] [PubMed] [Google Scholar]
  • 25.Crich D and Chandrasekera NS, Angewandte Chemie International Edition, 2004, 43, 5386–5389. [DOI] [PubMed] [Google Scholar]
  • 26.Ito Y and Ogawa T, Angewandte Chemie International Edition in English, 1994, 33, 1765–1767. [Google Scholar]
  • 27.Pistorio SG, Yasomanee JP and Demchenko AV, Organic Letters, 2014, 16, 716–719. [DOI] [PubMed] [Google Scholar]
  • 28.Kim KS, Fulse DB, Baek JY, Lee B-Y and Jeon HB, Journal of the American Chemical Society, 2008, 130, 8537–8547. [DOI] [PubMed] [Google Scholar]
  • 29.Pongener I, Pepe DA, Ruddy JJ and McGarrigle EM, Chemical Science, 2021, 12, 10070–10075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Elferink H, Mensink RA, White PB and Boltje TJ, Angew Chem Int Ed Engl, 2016, 55, 11217–11220. [DOI] [PubMed] [Google Scholar]
  • 31.Gucchait A and Misra AK, Org Biomol Chem, 2019, 17, 4605–4610. [DOI] [PubMed] [Google Scholar]
  • 32.Crich D and Sun S, Journal of the American Chemical Society, 1998, 120, 435–436. [Google Scholar]
  • 33.Crich D and Chandrasekera NS, Angew Chem Int Ed Engl, 2004, 43, 5386–5389. [DOI] [PubMed] [Google Scholar]
  • 34.Hassan AA and Oscarson S, European Journal of Organic Chemistry, 2020, 2020, 6102–6108. [Google Scholar]
  • 35.Codée JDC, Hossain LH and Seeberger PH, Organic Letters, 2005, 7, 3251–3254. [DOI] [PubMed] [Google Scholar]
  • 36.Jensen HH, Nordstrøm LU and Bols M, Journal of the American Chemical Society, 2004, 126, 9205–9213. [DOI] [PubMed] [Google Scholar]
  • 37.Mootoo DR, Konradsson P, Udodong U and Fraser-Reid B, Journal of the American Chemical Society, 1988, 110, 5583–5584. [Google Scholar]
  • 38.Pedersen CM, Nordstrøm LU and Bols M, Journal of the American Chemical Society, 2007, 129, 9222–9235. [DOI] [PubMed] [Google Scholar]
  • 39.Jensen HH, Pedersen CM and Bols M, Chemistry - A European Journal, 2007, 13, 7576–7582. [DOI] [PubMed] [Google Scholar]
  • 40.Mazzola EP, Parkinson A, Kennelly EJ, Coxon B, Einbond LS and Freedberg DI, Carbohyd Res, 2011, 346, 759–768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Crich D and Li L, The Journal of Organic Chemistry, 2007, 72, 1681–1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bejugam M and Flitsch SL, Organic Letters, 2004, 6, 4001–4004. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES